5-HTR2A, DRD2,and COMT Genes Polymorphisms and Olanzapine Plasma Concentration in Treatment of Early-onset Schizophrenia
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
In this study,investigators will recruit 100 DSM-Ⅴdefined EOS Han patients, older than 7
years old and onset of illness before 17 years old, and all EOS patients will receive a
8-week systematic olanzepine titration treatment and a battery of assessments of treatment
effect and safety. Blood olanzepine plasma concentration will be tested regularly and
genotyping of 8 polymorphisms of 5-HTR2A, DRD2 and COMT genes will be conducted by Polymerase
Chain Reaction （PCR）, Restriction Fragment Length Polymorphism (RFLP) and TaqMan probes
genotyping technology. The aim of the study is to explore the predictive factors on
olanzepine treatment response in EOS, which can guide the individualized treatment and
improve the cure rate of EOS in clinical setting.